Industry Perspectives

Agilent presents its integrated mass spectrometry and chromatography solutions at ASMS 2026

New ICP-MS, GC, and LC/MS solutions aim to streamline complex workflows, reduce downtime, and improve analytical confidence across laboratories.
Written byAgilent Technologies
| 3 min read
Diverse group of young adult students listening to their mature adult professor during a chemistry lecture in a lab

credit: istock.com/zamrznutitonovi

Register for free to listen to this article
Listen with Speechify
0:00
3:00

SANTA CLARA, California — May 29, 2026 – Agilent Technologies Inc. (NYSE: A) will showcase its latest mass spectrometry and chromatography innovations at the 74th ASMS Conference on Mass Spectrometry and Allied Topics, taking place May 31–June 4, 2026, in San Diego, California. The company will highlight integrated solutions designed to simplify complex workflows, improve data confidence, and deliver more consistent analytical results.

Agilent will feature solutions spanning elemental analysis, molecular mass spectrometry, and intelligent chromatography platforms. These innovations are designed to streamline workflows, improve data quality, and deliver more consistent, confident results across laboratory applications.

Agilent 9500 Triple Quadrupole ICP‑MS

The Agilent 9500 ICP‑MS is designed to simplify the transition from single quadrupole to triple quadrupole ICP‑MS while maintaining familiar workflows. The system introduces innovations including Air Cell and Advanced Helium Mode (AHM), enabled by Agilent's proprietary Dual‑Cell System (DCS). The system delivers confident interference removal and fast acquisition for advanced trace elemental analysis.

Agilent 8890B and 8860B GC Systems with GC Assist

Featuring new GC Assist instrument intelligence, these GC systems combine updated hardware with integrated monitoring, diagnostics, and guided troubleshooting. The platforms are designed to help laboratories improve data quality, reduce unplanned downtime, and operate more efficiently across routine analytical applications.

Agilent Multi‑Attribute Method (MAM) Solution

Designed to support adoption of LC/HRMS in regulated biopharmaceutical quality control environments, Agilent’s MAM solution integrates software, instrumentation, and consumables into a single workflow. The solution enables monitoring of multiple critical quality attributes and supports routine QC workflows in regulated environments through integration with OpenLab CDS and high‑resolution mass spectrometry systems such as the Agilent 6230C LC/TOF.

Agilent Events at ASMS 2026

Agilent User Group Meeting

Agilent will host a User Group Meeting on Sunday, May 31, from 8:00 a.m. to 1:00 p.m., at the Hard Rock Hotel San Diego (207 Fifth Ave, San Diego, CA 92101). The meeting will bring together industry experts and customers to discuss analytical workflows, emerging technologies, and real-world laboratory challenges.

Agilent Breakfast Sessions

Agilent will also host a series of breakfast sessions from Monday, June 1, through Wednesday, June 3, from 7:00 a.m. to 8:15 a.m., at the San Diego Convention Center, featuring presentations from customers and Agilent experts.

  • Monday, June 1

Sessions will focus on multi‑attribute method (MAM) solutions and laboratory productivity. The MAM session will feature presentations from Jahziel Chase (Northeastern University) and Melissa Sato (Agilent Technologies), highlighting approaches to confident biologics analysis. The laboratory productivity session will include presentations from Jeffrey McDonald (University of Texas Southwestern Medical Center) and Alan Owens (Agilent Technologies), focusing on workflow efficiency and operational best practices.

  • Tuesday, June 2

Sessions will cover multiomics discovery and simplified elemental analysis, including a presentation by Gary Patti (Washington University in St. Louis) on large-scale omics profiling and a session led by Phil Lowenstern and Mark Kelinske (Agilent Technologies) on mitigating ICP‑MS interferences.

  • Wednesday, June 3

Sessions will explore the laboratory ecosystem and biotherapeutics analysis, with presentations from Brian Rivera, Andreas Otto, Patrick Batoon, and Russell Burge (Agilent Technologies) addressing unified data systems, Agilent’s Small-Form-Factor Quadrupole LC/MS Evolution and advanced LC/MS workflows, while Russell Burge and Stephen Sciuto (Agilent Technologies) will discuss biotherapeutic characterization.

Additional information on these and other Agilent activities at ASMS is available at Agilent at ASMS.

In addition to product demonstrations, Agilent experts will participate in technical sessions and poster presentations throughout the conference, sharing insights into emerging analytical approaches and real-world laboratory challenges. Attendees are invited to visit Agilent at booth #601 as well as the Agilent hospitality suite in Grand Ballrooms 1–4 at the Marriott Marquis San Diego to engage with experts, explore live demonstrations, and learn how integrated workflows can support quality, safety, and productivity across the analytical lifecycle.

Agilent is a long-standing corporate member and supporter of ASMS and continues to collaborate closely with the scientific community to advance the role of mass spectrometry in solving today’s most important analytical challenges.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A scientist in a white lab coat looking into a microscope in a brightly lit modern laboratory.
Learn how developmental and reproductive toxicology study selection supports regulatory decision-making and generates meaningful nonclinical safety data.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue